Skip to main content

Table 3 General features of the trials which were included in this analysis

From: Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials

Trials Type of study Patients enrollment period No of patients using 100 mg CANA (n) No of patients using 300 mg CANA (n) Trial number
Blonde 2016 [9] RCT 2009-2013 724 721 NCT00968812 + NCT01106651
Forst 2014 [10] RCT 2010-2012 113 114 NCT01106690
Neal 2015 [11] RCT 2009-2011 692 690 NCT01032629
Gonzalez 2013 [12] RCT 2010-2012 368 367 NCT01106677
Inagaki 2013 [13] RCT 2009-2010 74 75 NCT01022112
Inagaki 2014 [14] RCT 2011-2012 127 253 NCT01387737
Stenlof 2013 [15] RCT 2010-2012 195 197 NCT01081834
Wilding 2013 [16] RCT 2010-2012 157 156 NCT01106625
Yale 2013 [17] RCT - 90 89 -
Rosenstock 2012 [18] RCT 2008–2009 64 128 NCT00642278
Total no    2604 2790  
  1. Abbreviations: RCT randomized controlled trials, CANA canagliflozin